News

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

May 17, 2017

iStock_000028679138_Small

SAN DIEGO, May 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a

AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov

May 16, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

NEW YORK, May 15, 2017 –– AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +37.64% a world leader in cannabinoid research and development, today announced that information on the company’s Bioavailability Study on Dronabinol in a controlled-release, functional chewing gum form is now

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

May 3, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

SAN DIEGO, May 3, 2017 — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol

March 28, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

SAN DIEGO, March 28, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API

Medical Marijuana, Inc. Investment AXIM Biotech Retains Ora To Manage Upcoming Product Development And Clinical Trials On Glaucoma And Dry Eye Indications

March 21, 2017

general-hemp-blog-images-11-16-16-ver1

NEW YORK, March 21, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM®Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, has

Medical Marijuana, Inc. Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome (IBS) With CanChew Plus® Cannabidiol (CBD) Chewing Gum

March 7, 2017

general-hemp-blog-images-11-16-16-ver1

NEW YORK, March 7, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase

Medical Marijuana, Inc. Clarifies Operations Unaffected by White House Statements Hinting at Recreational Marijuana Crackdown

March 1, 2017

general_hemp_blog_images_03-01-17_ver1 (1)

SAN DIEGO, March 1, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, is reassuring customers, shareholders, and the public that the company’s operations in the federally legal hemp cannabidiol (CBD) market are unaffected by

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

January 18, 2017

general-hemp-blog-images-11-16-16-ver1

NEW YORK, Jan 18, 2017 (GLOBE NEWSWIRE via COMTEX) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +25.67% a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus®

AXIM® Biotech Attends Biotech Showcase and J.P. Morgan Healthcare Conferences in San Francisco

January 10, 2017

general-hemp-blog-medical-cannabis-17-01-10-ver1

NEW YORK, Jan 10, 2017 — AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +23.30% a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is meeting with

Medical Marijuana, Inc. Investment AXIM® Biotech Receives Positive PK Data Results for CanChew Plus(R) CBD Gum

January 9, 2017

general-hemp-blog-images-11-16-16-ver1

AXIM Biotechnologies Announces Positive Pharmacokinetic (PK) Data Results on Proprietary Delivery Method for Cannabinoids in Chewing Gum SAN DIEGO, CA — (Marketwired) — 01/09/17 — Medical Marijuana, Inc.(OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced